ViiV Healthcare seeks FDA approval for fostemsavir to treat HIV-1 infection

This article was originally published here

The company has completed the submission of a new drug application (NDA) to the regulator for fostemsavir. Fostemsavir, an investigational prodrug of temsavir, is a first-in-class HIV-1 attachment

The post ViiV Healthcare seeks FDA approval for fostemsavir to treat HIV-1 infection appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply